Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2015

Jun 8, 2015

34632_dirs_2015-06-08_ced3c4d2-aec5-458d-9aff-bd34d10d2ff3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2015-06-04

Reporting Person: KOZIN MARC D (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-06-04 Stock Option (right to buy) $36.19 A 12000 Acquired 2025-06-04 Common Stock (12000) Direct

Footnotes

F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 4, 2015.